Kura Oncology, Inc. (KURA) Balance Sheet

NASDAQ: KURAAssets, liabilities, debt and equity over 10 years.

KURA balance sheet, 2025

December 31, 2025 · U.S. dollars

$738.4M assets = $564.2M liabilities + $174.1M equity

What it owns$738.4MCash & ST investments: $667.2M (90.4%)Cash & ST investments$667.2M · 90%Receivables: $12.6M (1.7%)Inventory: $413,000 (0.1%)Other current: $28.4M (3.8%)PP&E: $15.2M (2.1%)Other non-current: $14.5M (2.0%)=How it is financed$738.4MCurrent liabilities: $117.0M (15.8%)Current liabilities$117.0M · 16%Long-term debt: $9.7M (1.3%)Other LT liabilities: $437.5M (59.3%)Other LT liabilities$437.5M · 59%Shareholders’ equity: $174.1M (23.6%)Shareholders’ equity$174.1M · 24%

Both columns are drawn to the same scale: what KURA owns equals what it owes plus shareholders’ equity. Hover a block for its value.

KURA financial health

Current ratio6.06
Comfortable · current assets cover current liabilities 6.06×
Debt / equity0.12
Low leverage · $0.12 of debt for each $1 of equity
Equity / assets23.6%
Balanced · of assets funded by shareholders
Cash / debt3,261.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

KURA balance sheet trends, 2016–2025

Kura Oncology, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$69.8M2016$738.4M2025+30.0%/yr
Total liabilities$12.9M2016$564.2M2025+52.1%/yr
Shareholders’ equity$56.9M2016$174.1M2025+13.2%/yr
Cash & short-term investments$67.8M2016$667.2M2025+28.9%/yr
Total debt$7.3M2016$20.5M2025+12.1%/yr
Net cash (debt)$60.5M2016$646.8M2025+$586.3M
Working capital$63.4M2016$591.7M2025+$528.3M
Book value per share$3.042016$1.992025−4.6%/yr
Current ratio12.6220166.062025−6.57
Debt / equity0.1320160.122025−0.01
Shares outstanding18.7M201687.7M2025+18.7%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

KURA assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

KURA liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

KURA debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

KURA balance sheet

Kura Oncology, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$667.2M$727.4M$424.0M$438.0M$518.0M$633.3M$236.9M$179.0M$93.1M$67.8M
Cash & equivalents$149.1M$224.5M$37.3M$51.8M$90.7M$325.5M$26.1M$16.1M$11.4M$9.7M
Short-term investments$518.1M$502.9M$386.6M$386.2M$427.3M$307.8M$210.8M$162.9M$81.7M$58.1M
Receivables$12.6M$6.1M$2.8M$900,000$1.4M$0$30,000$224,000$216,000$295,000
Inventory$413,000$0$0$0$0$0$0$0$0$0
Other current assets$28.4M$11.3M$5.7M$7.5M$2.9M$4.0M$2.7M$2.0M$1.3M$725,000
Total current assets$708.7M$744.8M$432.5M$446.4M$522.3M$637.3M$239.6M$181.2M$94.6M$68.8M
Property, plant & equipment (net)$15.2M$7.5M$8.9M$6.4M$8.2M$8.4M$278,000$0$10,000$40,000
Goodwill & intangible assets$0$0$0$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$14.5M$7.8M$7.6M$3.5M$3.5M$1.6M$2.1M$1.2M$1.2M$971,000
Total assets$738.4M$760.2M$448.9M$456.3M$534.1M$647.2M$242.0M$182.4M$95.9M$69.8M
Liabilities
Accounts payable$5.0M$1.5M$2.3M$1.5M$3.2M$2.8M$3.5M$3.9M$1.2M$1.4M
Short-term debt$1.3M$4.5M$1.5M$2.3M$2.3M$5.1M$502,000—$1.5M$7.3M
Deferred revenue$49.0M$24.3M————————
Total current liabilities$117.0M$78.7M$35.3M$24.1M$22.5M$26.0M$15.6M$13.6M$10.0M$5.5M
Long-term debt$9.7M$6.9M$9.3M$9.2M$0$4.2M$7.2M$7.5M$5.6M$7.3M
Lease obligations$10.7M$7.1M$7.9M$4.9M$6.9M$7.7M————
Other long-term liabilities$437.5M$260.9M$7.1M$2.8M$5.0M$6.0M$377,000$279,000$388,000$170,000
Total liabilities$564.2M$346.5M$51.7M$36.0M$27.4M$36.3M$23.2M$21.4M$16.0M$12.9M
Shareholders' equity
Common stock & paid-in capital$9,000$8,000$7,000$7,000$7,000$7,000$5,000$4,000$3,000$2,000
Retained earnings (deficit)−$1.17B−$895.4M−$721.4M−$568.8M−$433.0M−$302.5M−$212.9M−$149.7M−$89.3M−$53.9M
Accumulated other comprehensive income$1.0M$764,000−$1.3M−$8.0M−$1.8M$46,000$331,000−$131,000−$49,000−$18,000
Total shareholders' equity$174.1M$413.6M$397.3M$420.3M$506.6M$610.9M$218.8M$161.0M$79.9M$56.9M
Key figures
Total debt$20.5M$16.6M$17.2M$14.0M$6.9M$15.0M$7.8M$7.5M$7.1M$7.3M
Net cash (debt)$646.8M$710.8M$406.8M$424.0M$511.1M$618.3M$229.1M$171.5M$86.0M$60.5M
Working capital$591.7M$666.1M$397.2M$422.4M$499.8M$611.3M$224.0M$167.6M$84.6M$63.4M
Tangible book value$174.1M$413.6M$397.3M$420.3M$506.6M$610.9M$218.8M$161.0M$79.9M$56.9M
Book value per share$1.99$4.80$5.43$6.27$7.64$11.51$5.22$4.57$3.44$3.04
Shares outstanding87.7M86.2M73.2M67.0M66.4M53.1M41.9M35.2M23.2M18.7M
Current ratio6.069.4612.2618.5623.2624.4915.3913.319.4312.62
Quick ratio5.819.3212.1018.2423.1324.3415.2213.169.3112.49
Debt / equity0.120.040.040.030.010.020.040.050.090.13
Equity / assets23.6%54.4%88.5%92.1%94.9%94.4%90.4%88.3%83.3%81.5%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 5, 2026); data from EODHD.

KURA financial position

At the end of fiscal 2025 (December 31, 2025), Kura Oncology had total assets of $738.4 million (down 2.9% from a year earlier), total liabilities of $564.2 million and shareholders' equity of $174.1 million. It held $667.2 million in cash and short-term investments against $20.5 million of debt, a net cash position of $646.8 million. Its current ratio was 6.06. In the latest quarter (ended June 30, 2026) total assets were $587.8 million and equity $48.4 million.

Related: KURA income statement, KURA cash flow statement, KURA key metrics. See the KURA stock overview for the latest quote and news.

KURA balance sheet FAQ

What are Kura Oncology's total assets?

Kura Oncology reported total assets of $738.4 million at the end of fiscal 2025 (December 31, 2025), compared with $760.2 million a year earlier.

How much debt does Kura Oncology have?

Kura Oncology had $20.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.12.

How much cash does Kura Oncology have?

Kura Oncology held $667.2 million in cash and short-term investments at the end of fiscal 2025; with $20.5 million of debt that is net cash of $646.8 million.

What is Kura Oncology's book value?

Kura Oncology's shareholders' equity (book value) was $174.1 million at the end of fiscal 2025, or $1.99 per share.

What is Kura Oncology's current ratio?

Kura Oncology had current assets of $708.7 million and current liabilities of $117.0 million, a current ratio of 6.06 (it can cover its short-term obligations).

Biotechnology: balance sheet